Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib.
Pilot
P R
PR
Sablinska
K
K
Owen
S
S
Hatfield
A
A
D000328:Adult; D000368:Aged; D001549:Benzamides; D015331:Cohort Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000453:epidemiology*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000453:epidemiology*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D013995:Time
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate